* Nektar Therapeutics press release [https://seekingalpha.com/pr/20298070-nektar-therapeutics-reports-third-quarter-2025-financial-results] (NKTR [https://seekingalpha.com/symbol/NKTR]): Q3 Non-GAAP EPS of $1.85 beats by $4.64.
* Revenue of $11.79M (-51.1% Y/Y) beats by $1.59M.
MORE ON NEKTAR THERAPEUTICS
* Nektar Therapeutics: Fairly Valued, High-Quality Biotech With Multiple Near-Term Catalysts [https://seekingalpha.com/article/4815930-nektar-therapeutics-fairly-valued-high-quality-biotech-multiple-near-term-catalysts]
* Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4811559-nektar-therapeutics-nktr-q2-2025-earnings-call-transcript]
* Nektar Therapeutics Q3 2025 Earnings Preview [https://seekingalpha.com/news/4515816-nektar-therapeutics-q3-2025-earnings-preview]
* Nektar Therapeutics gains amid takeover speculation [https://seekingalpha.com/news/4505309-nektar-therapeutics-gains-amid-takeover-speculation]
* Seeking Alpha’s Quant Rating on Nektar Therapeutics [https://seekingalpha.com/symbol/NKTR/ratings/quant-ratings]
Nektar Therapeutics Non-GAAP EPS of $1.85 beats by $4.64, revenue of $11.79M beats by $1.59M
Published 1 day ago
Nov 6, 2025 at 9:29 PM
Positive
Auto